RFK Jr. Opens Access to Experimental Peptides Without FDA Approval

HHS has directed the FDA not to act against pharmacies selling six experimental peptides, including BPC-157, KPV and TB-500. The decision was made without input from FDA scientists and drew criticism from medical experts warning of patient harm.

• HHS allowed sales of six peptides without FDA approval
• The list includes BPC-157, KPV and TB-500
• The decision was made without consulting FDA scientists
• The peptides remain experimental with unverified safety